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Abstract (X2-Macroglobiilin ((X2M) binds a number of cyto-
kines, including transforming growth factor-pi (TGF-pi) and 
TGF-(i2. The affinity of these interactions depends on the a2M 
conformation. In this investigation, we treated human (X2M with 
as-dichlorodiammineplatinum (II) (cis-Pt), a crosslinking re-
agent that partially 'locks' the rx2M conformation, and then with 
methylamine to generate a preparation (o^M-P/M) consisting of 
stable a2M conformational intermediates. a2M-P/M bound 
TGF-pl and TGF-p2 with higher affinity than any other form of 
a2M studied to date. The equilibrium dissociation constants were 
14 and 2 nM for TGF-pi and TGF-P2, respectively. a2M-P/M, 
at 100 nM, neutralized the activity of TGF-pi by about 75% in 
an endothelial cell proliferation assay. The equivalent concentra-
tion of native oc2M or methylamine-modified a2M had no effect. 
These studies demonstrate that the potential of a2M as a 
cytokine carrier and neutralizer may not be fully realized in 
either the native or completely activated conformations. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
(X2-Macroglobulin (0C2M) is a naturally occurring protein in 
the blood which functions not only as a proteinase inhibitor 
but also as a carrier of specific cytokines, including transform-
ing growth factor-pi (TGF-pi), platelet-derived growth fac-
tor-BB, and nerve growth factor-P [1,2]. The binding affinities 
of 0C2M for different cytokines vary widely and are not always 
affected similarly when the 0:2 M is modified by proteinases [1-
3]. Many cytokines do not bind to 0:2 M at all, including 
PDGF-AA, interferon-y, colony stimulating factor-1, and cil-
iary neurotrophic factor [1,2,4,5]. Thus, a2M may function to 
neutralize cytokines, with partial specificity, in normal homeo-
stasis and in select disease states. 
CC2M in the blood is almost entirely in the native conforma-
tion. This form of 0C2M is fully functional as a proteinase 
inhibitor but not recognized by cellular receptors [6]. When 
treated with small primary amines, such as methylamine, na-
tive a2M undergoes a major conformational change [7,8]. The 
resulting structure, which is referred to as activated a2M, 
retains no proteinase inhibitory activity but is recognized by 
o^M-specific receptors, primarily in the liver, and thus rapidly 
cleared from the circulation [6]. Many proteinases induce a 
conformational change in cc2M which is equivalent to that 
caused by methylamine [9,10]; however, before adopting the 
'fully activated' conformation, the 012M apparently transitions 
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through a series of variably stable structural intermediates 
[11-15]. 
Very little is known about cytokine binding to a2M con-
formational intermediates; however, these intermediates may 
be identified as a small sub-population within purified native 
a2M preparations [16,17]. In the present investigation, we 
utilized an oc2M chemical modification protocol which has 
been previously characterized for its potential to stabilize 
CC2M conformational intermediates [12,18]. The protocol uti-
lizes the reagent, cw-dichlorodiammineplatinum (II) (cis-Pt), 
as an amino acid side-chain crosslinker to partially lock the 
a2M conformation prior to adding methylamine. Treatment 
of cw-Pt-modified 0C2M with methylamine results in only par-
tial reorganization of the a2M structure, as determined by 
nondenaturing PAGE, electron microscopy, and receptor rec-
ognition experiments [12,13,18,19]. 
The studies presented here demonstrate that oc2M, modified 
with cis-Pt and methylamine, binds TGF-pi and TGF-p2 with 
higher affinity than any other CC2M preparation studied to 
date. To confirm the results of our equilibrium cytokine-bind-
ing analyses, we performed endothelial cell proliferation as-
says. TGF-pi inhibited endothelial cell growth as expected 
and oc2M-P/M neutralized this activity while native oc2M 
and a2M-methylamine, at the equivalent concentration, were 
ineffective. 
2. Materials and methods 
2.1. Materials 
Porcine TGF-pt, which is identical in sequence to human TGF-pl, 
was from R&D Systems (Minneapolis, MN, USA). Human TGF-P2 
was from Genzyme (Cambridge, MA, USA). TGF-pl and TGF-p2 
were radioiodinated according to the method of Ruff and Rizzino 
[20]. Specific activities were 100-200 uCi/ug. Methylamine-HCl, chlor-
amine-T, bovine serum albumin (BSA) and fetal bovine serum were 
from Sigma (St. Louis, MO, USA). Dulbecco's modified Eagle's me-
dium (DMEM), trypsin-EDTA, and Earle's balanced salts solution 
were from GIBCO BRL (Gaithersburg, MD, USA). Na125I was 
from Amersham (Arlington Heights, 1L, USA). Acidic fibroblast 
growth factor and basic fibroblast growth factor were from Promega 
(Madison, WI, USA), ife(sulfosuccinimidyl) suberate (BS3) and Iodo-
beads were from Pierce (Rockford, IL, USA). Cis-Pt was from Al-
drich (Milwaukee, WI, USA). 
2.2. Preparation of a.2M and 0L2M derivatives 
CI2M was purified from human plasma by the method of Imber and 
Pizzo [21]. The concentration of (X2M was determined by measuring 
the absorbance at 280 nm, using an A^, i(.m of 8.93 [22]. All purified 
native 0C2M preparations were screened for the presence of trace levels 
of partially activated forms by incubation with 125I-TGF-pi followed 
by nondenaturing PAGE, as previously described [17]. Any native 
012M preparations that showed TGF-pl-binding to o^M species 
with increased mobility were discarded. 
CI2M-MA was prepared by dialyzing native 012M against 200 mM 
methylamine-HCl in 50 mM Tris-HCl, pH 8.2, for 12 h at 22°C, 
followed by extensive dialysis against 20 mM sodium phosphate, 
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150 mM NaCl, pH 7.4 (PBS) at 4°C. Complete modification of native 
a 2 M by methylamine was confirmed by loss of trypsin binding activ-
ity ( > 96%) [23] and by the characteristic increase in mobility by 
nondenaturing PAGE [24,25]. 
0(2 M-P was prepared by reacting native 012M with 1.6 mM cis-Pt for 
6 h at 37°C. Unreacted cis-Pt was removed by extensive dialysis 
against PBS. 0C2M-P/M was prepared by dialyzing 0C2M-P against 
200 mM methylamine-HCl in 50 mM Tris-HCl, pH 8.2, for 12 h at 
22°C, followed by extensive dialysis against PBS. 
2.3. Determination of apparent equilibrium dissociation constants 
Equilibrium dissociation (KA) constants were determined by the 
BS3-rapid crosslinking method, as has been described by our labora-
tory [1,2,5,26]. Cytokine-binding to a 2M is modeled as a two-step 
reaction: 
kl 
A + C^AC-^AC* (1) 
fc-i 
A is unbound 012M, C is unbound cytokine, AC is reversibly asso-
ciated (noncovalent) cc2M-cytokine complex, and AC* is irreversibly 
associated (covalent) o^M-cytokine complex, formed by thiol-disulf-
ide exchange. For TGF-(51 and TGF-|32, reversible binding to o^M 
occurs fairly rapidly and fc2 is sufficiently small so that it may be 
ignored in the determination of Ku values [2]. 
In the experiments presented here, various concentrations of rx2M-P 
or ot2M-P/M (0.002-2.5 uM) were incubated with
 125I-TGF-pl or 125I-
TGF-P2 (1.0 nM) in PBS with 75 uM BSA, for 30 min at 37°C. The 
rapid-crosslinking agent, BS3 (in H2O), was then added at a final 
concentration of 5 mM for 1 min. For each 0C2M concentration, an 
identical control incubation was treated with vehicle (H2O) instead of 
BS3. Crosslinking reactions were terminated instantaneously by acid-
ification [4], Samples were then denatured in 2.0% SDS for 30 min at 
37°C, supplemented with Tris-HCl (100 mM) and glycerol (10%), and 
subjected to SDS-PAGE. The gels were sliced into 3 mm sections and 
the radioactivity content of each section was determined in a gamma 
counter. 125I-Cytokine recovered in association with a 2M (ACe) in-
cluded BS3-stabilized AC and AC*. Free cytokine (in the gels) (Ce) 
included C plus AC which was not BS3-stabilized. AC* was quanti-
tated independently by SDS-PAGE analysis of samples that were not 
BS3-treated. Apparent KA values were determined according to the 
following equation: 
&-(T)GK-') 
z is the BS3-crosslinking efficiency, a constant (0 < z < 1) for each 
cytokine and oc2M derivative which does not vary as a function of the 
a 2M concentration. ACe is related to AC by the relationship: 
[ACe] = z[AC]. Assumptions involved in the use of this method have 
been reviewed [1,2]. These include that the KD value reflects a single 
cytokine-binding site per a 2M and that all of the 0C2M in a given 
preparation binds cytokine with equal affinity. 
The methods for preparing CX2M-P and o^M-P/M involve the bind-
ing of an average of 17 mol platinum per mol of a 2M [12]. Since there 
is almost certainly heterogeneity in the extent of platinum binding and 
because the amino acids modified probably vary, ct2M-P and oc2M-P/ 
M must be viewed as heterogeneous preparations in which different 
molecules may bind 125I-TGF-|3 with different affinities. Each KA value 
determined for oc2M-P or o^M-P/M, by the BS
3-rapid crosslinking 
method, is a preparation-averaged constant, related to the different 
Ka values of n different 0C2M species (A\) by the following equation: 
1 _ 1 Ti=1A, | 1 Z t u ^ i j 1 Zti.2,4^ | ( 3 ) 
K& -Kd! K^AT KA2 KA2AT KA, KI3AT 
AT is the total concentration of all a 2M species in the preparation 
(sum of A[). As an example, if an 012M preparation consists of two 
species in equal proportion, which bind a given cytokine with KA 
values of 100 and 500 nM, then the preparation-averaged KA value 
would be 167 nM. When multiple species are present in an a 2M 
preparation, plots of CJACe against l/[AT] (according to Eq. 2) re-
main linear. Preparation-averaged KA values are not affected by differ-
ences in the BS3-crosslinking efficiencies (z values) amongst various 
a 2M species within a given preparation. 
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2.4. Inhibition of endothelial cell growth 
FBHE cells were maintained in DMEM supplemented with 10% 
FBS, 20 ng/ml acidic fibroblast growth factor, and 80 ng/ml basic 
fibroblast growth factor. Cultures were passaged at subconfluence 
with trypsin-EDTA. FBHE cell proliferation assays were performed 
in dilute (0.2%) serum as previously described [26,27]. Briefly, FBHE 
cells were plated in 24-well culture plates (2X104 cells/well) and in-
cubated in DMEM with 10% FBS for 15 h. After washing, fresh 
DMEM, supplemented with 0.2% FBS and TGF-pi, was added. 
Some cultures were simultaneously treated with native oc2M, a2M-P, 
012M-P/M, or 012M-MA. After incubation for 30 h, [3H]thymidine was 
added for an additional 18 h. The cells were then harvested and 
radioactivity incorporation was measured in a scintillation counter. 
3. Results 
3.1. Nondenaturing PAGE analysis of the (X2M derivatives 
Nondenatur ing P A G E is commonly used to analyze 0:2 M 
conformation [24,25]. Fig. 1 shows a representative nondena-
turing P A G E experiment in which the four 0C2M preparations 
were compared. Native 0C2M migrated in a single Coomassie-
stained band. The mobility of methylamine-modified 0C2M was 
increased compared with that of native 012M reflecting the 
transition to the fully activated conformation. As expected, 
the mobility of 0C2M-P/M was intermediate between native 
0C2M and CC2M-IV1A, reflecting partial conformational change 
[12,18]. The low mobility bands in the oc2M-P and oc2M-P/M 
preparations suggest some intermolecular o^M-crosslinking, 
due to the high concentration of cis-Pt used. 
3.2. Equilibrium binding of1251-cytokines to a^M-P and 
a2M-PIM 
The BS3-rapid crosslinking method was used to determine 
Kd values for the binding of
 125I-TGF-(31 and 125I-TGF-|32 to 
oe2M-P and a 2 M - P / M . In preliminary time-course experi-
ments, noncovalent binding of each cytokine to the modified 
CC2M derivatives maximized within 15 min (results not shown). 
Fig. 2A shows a representative autoradiograph in which 1 2 5I-
TGF-|31 was incubated with various concentrations of 0C2M-P 
for 30 min, and then with BS3 . The amount of 1 2 5 I -TGF- |31-
CC2 M-P complex detected was dependent on the o^M-P con-
centration. In the control gel, which contained samples that 
were treated with vehicle instead of BS3 , the amount of 1 2 5I-
T G F - p l - o ^ M - P complex was consistently less than 20% of 
N P P/M MA 
Fig. 1. Nondenaturing PAGE analysis of 012M derivatives. Native 
a 2M (N), a2M-P (P), a2M-P/M (P/M) and a2M-MA (MA) are 
shown. The gel was stained with Coomassie blue R-250. 
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Fig. 2. Equilibrium binding of 125I-TGF-pi to a2M-P and a2M-P/M.
 125I-TGF-pi was incubated with a2M-P for 30 min at 37°C. The samples 
were pulse-exposed to 5 mM BS3 and subjected to SDS-PAGE and autoradiography. The autoradiograph of a representative gel is shown in 
(A). The concentrations of a2M-P were 2 nM (lane a), 4 nM (lane b), 6 nM (lane c), 9 nM (lane d), 13 nM (lane e), 20 nM (lane f), 30 nM 
(lane g), 45 nM (lane h), 67 nM (lane i), 0.1 |J.M (lane j), and 0 nM (lane k). The terms, ACe, AC*, and Ce are defined in the text. B: Results 
of BS3-rapid crosslinking studies analyzing the binding of TGF-pi to native a2M (A), a2M-P (o), a2M-P/M (□) and a2M-MA (0). The re-
sults of four separate experiments were averaged and plotted according to Eq. 2 in the text. 
that detected with BS3 (not shown). Thus, AC* represented 
only a small fraction of the covalent a2M-P-TGF-|31 complex 
recovered after BS3 treatment. Similar results were obtained 
when a2M-P/M was substituted for oc2M-P and when TGF-(32 
was studied. 
Fig. 2B shows plots of CJACe against l/AT for the binding 
of 125I-TGF-pi to native a2M, a2M-P, a2M-P/M and oc2M-
MA. The presented graphs were generated from the results of 
at least four separate experiments. Individual experiments, 
with TGF-(31 and TGF-(32, were analyzed using similar plots, 
Table 1 
Equilibrium dissociation constants for 
Cytokine 
TGF-pi 
TGF-P2 
0C2M-P 
(nM) 
36±2 
a2M-P/M 
(nM) 
14±4 
2 ± 1 
125I-TGF-P-binding to a2M 
Native a2M 
(nM) 
320 ±65 
14± 3 
a2M-MA 
(nM) 
82±6 
15±2 
Results were determined using the BS3-rapid crosslinking method. 
Each value represents the mean±SE (« = 4). The K& values for the 
binding of each cytokine to native a2M and a2M-MA have been 
presented previously [1,2]. 
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+ TGF-B1 
Fig. 3. Effects of o^M on TGF-(il activity in an endothelial cell 
proliferation assay. FBHE cells were incubated with 10 pM TGF-pi 
in the presence and absence of 100 nM native CX2M, 0C2M-P, 012M-
MA, or 0C2M-P/M. The culture medium contained 0.2% FBS. After 
30 h, 1 (xCi/ml [3H]thymidine was added to the cultures for an addi-
tional 18 h. [3H]Thymidine incorporation was then determined and 
expressed as a percentage of that observed in control cultures, 
which were not exposed to 012M or TGF-pi. **Statistically signifi-
cant differences (P < 0.005). 
which were all apparently linear, as expected. A"<j values from 
individual experiments were averaged to obtain the constants 
presented in Table 1. Binding constants for the interaction of 
TGF-pl and TGF-p2 with native a2M and a2M-MA have 
been presented previously [2]. 
As shown in Table 1, a2M-P/M and a2M-P bound TGF-01 
with higher affinity than oc2M-MA. The K^ for the binding of 
TGF-fSl to a2M-P/M (14 nM) was decreased by a factor of 23 
compared with the K& for TGF-P 1 binding to native cc2M 
(320 nM). The Kd for the binding of TGF-p2 to oc2M-P/M 
(2 nM) is the lowest binding constant reported for any cyto-
kine and any cc2M derivative studied to date. 
3.3. a2M-P and a2M-PIM counteract the activity of TGF-$ 
in cell culture 
TGF-P inhibits FBHE proliferation in cell culture and this 
activity is counteracted by oe2M [26,27]. Experiments with a 
variety of human cc2M derivatives and oc-macroglobulins from 
different species have shown that the fraction of TGF-P ac-
tivity neutralized directly correlates with the affinity of the oc-
macroglobulin/TGF-P interaction [3,26,27]. Since the K& val-
ues determined for cytokine binding to a2M-P and oc2M-P/M 
were preparation-averaged values, we wished to confirm that 
these constants accurately predict the cytokine-binding and/or 
-neutralizing activities of the a 2 M preparations. Fig. 3 shows 
the results of FBHE proliferation experiments in which 10 pM 
TGF-P 1 inhibited [3H]thymidine incorporation by an average 
of 84%. A fairly low concentration of each a2M derivative 
(100 nM) was added to different FBHE cultures such that 
high-affinity TGF-P-a2M interactions would be selectively de-
tected. As expected, native a 2 M did not significantly affect 
[3H]thymidine incorporation while a2M-MA had only a small 
effect which was not statistically significant at the P < 0.05 
level. By contrast, a2M-P substantially reversed the growth 
inhibition caused by TGF-pi and oe2M-P/M was even more 
effective. The 'double-stars' in Fig. 3 indicate statistically sig-
nificant differences at the P < 0.005 level. The results of these 
FBHE growth inhibition studies confirm that the K& values, 
determined by the BS3-rapid crosslinking method, accurately 
predict the TGF-P-neutralizing activities of the modified a 2 M 
preparations, even though these preparations are heterogene-
ous. 
4. Discussion 
Native oc2M functions as a physiologically significant carrier 
of TGF-P in the blood [1]. Circulating a2M-TGF-P com-
plexes are mostly noncovalent and reversible [28,29]. Thus, 
ce2M may provide a stable pool of slowly releasable cytokine 
activity, in the plasma, under normal homeostatic conditions. 
At sites of inflammation or other pathological processes that 
occur in tissue, concentrations of TGF-P isoforms may be in 
rapid flux and a 2 M may serve to buffer cells against the full 
impact of changing TGF-p activity. Cell culture experiments, 
in which cells are exposed to a bolus of cytokine or allowed to 
respond to autocrine-secreted cytokines, probably model the 
microenvironment of tissues more closely than plasma. In 
these in vitro systems, a 2 M has been shown to regulate cel-
lular growth and gene expression by binding TGF-P 
[26,27,30,31]. 
The binding affinity of oc2M for TGF-P isoforms and other 
cytokines is dependent on the conformational state of the 
a 2 M [1]. While most previous studies have been conducted 
using native oc2M or fully activated, methylamine-modified 
oc2M, the studies presented here demonstrate that neither of 
these well-studied a2M conformations have optimized cyto-
kine binding activity. a2M-P and cc2M-P/M bound TGF-pi 
and TGF-P2 with higher affinity than previously studied 
forms of a2M. The same derivatives also neutralized the ac-
tivity of TGF-P 1 in FBHE proliferation assays, confirming 
the validity of the K& values, determined by the BS3-rapid 
crosslinking method. Thus, these chemically modified a2M 
derivatives represent superior TGF-P-binding agents. 
Based on hydrodynamic and electron microscopy studies, 
we previously proposed that a2M-P/M may model intermedi-
ates which occur transiently during oc2M conformational 
change in vivo [12,13,18,19]. However, electron microscopy 
images of oc2M-P already show some changes in structure 
compared with native a2M [12]. Thus, the model of cis-Pt 
as an oc2M 'conformational lock' may be oversimplified. The 
increased TGF-P-binding affinity of oc2M-P, compared with 
native oc2M, supports the hypothesis that cw-Pt alone induces 
some changes in the structure of oc2M that are yet to be 
defined. 
In conclusion, we have shown that the TGF-P-binding ac-
tivity of oc2M can be modified by reagents which alter the 
conformation of the molecule. The newly described deriva-
tives may be useful as TGF-P-activity modifiers in vitro and 
in vivo. Whether the same a 2 M modification protocol will 
enhance binding of other cytokines remains to be determined. 
Acknowledgements: This work was supported in part by National In-
stitutes of Health Grant CA-53462. D. Webb is a fellow of the Amer-
ican Heart Association, Virginia Affiliate. The authors would like to 
thank Janice Wen for excellent technical assistance. 
References 
[1] Gonias, S.L., LaMarre, J., Crookston, K.P., Webb, D.J., Wolf, 
B.B., Lopes, M.B.S., Moses, H.L. and Hayes, M.A. (1994) Ann. 
NY Acad. Sci. 737, 273-290. 
D.J. Webb, S.L. GoniaslFEBS Letters 410 (1997) 249-253 253 
[2] Crookston, K.P., Webb, D.J., Wolf, B.B. and Gonias, S.L. 
(1994) J. Biol. Chem. 269, 1533-1540. 
[3] Webb, D.J., Weaver, A.M., Atkins-Brady, T.A. and Gonias, S.L. 
(1996) Biochem. J. 320, 551-555. 
[4] Bonner, J.C. and Osornio-Vargas, A.-R. (1995) J. Biol. Chem. 
270, 16236-16242. 
[5] Wolf, B.B. and Gonias, S.L. (1994) Biochemistry 33, 11270-
11277. 
[6] S.V. Pizzo, S.L. Gonias, in: P.M. Conn (Ed.), The Receptors. 
Vol. 1. Academic Press, Orlando, FL, 1984, pp. 178-221. 
[7] Sottrup-Jensen, L., Petersen, T.E. and Magnusson, S. (1980) 
FEBS Lett. 121, 275-279. 
[8] Howard, J.B. (1981) Proc. Natl. Acad. Sci. USA 78, 2235-2239. 
[9] Gonias, S.L., Reynolds, J.A. and Pizzo, S.V. (1982) Biochim. 
Biophys. Acta 705, 306-314. 
[10] Bjork, I. and Fish, W.W. (1982) Biochem. J. 207, 347-356. 
[11] Strickland, D.K., Steiner, J.P., Migliorini, M. and Battey, F.D. 
(1988) Biochemistry 27, 1458-1466. 
[12] Gonias, S.L. and Figler, N.L. (1989) J. Biol. Chem. 264, 9565-
9570. 
[13] Marshall, L.B., Figler, N.L. and Gonias, S.L. (1992) J. Biol. 
Chem. 267, 6347-6352. 
[14] Steiner, J.P., Bhattacharya, P. and Strickland, D.K. (1985) Bio-
chemistry 24, 2993-3001. 
[15] Roche, P.A. and Pizzo, S.V. (1988) Arch. Biochem. Biophys. 267, 
285-293. 
[16] Borth, W. (1994) Ann NY Acad. Sci. 737, 267-272. 
[17] LaMarre, J., Hayes, M.A., WoUenberg, G.K., Hussaini, I., Hall, 
S.W. and Gonias, S.L. (1991) J. Clin. Invest. 78, 39-44. 
[18] Gonias, S.L. and Pizzo, S.V. (1981) J. Biol. Chem. 256, 12478-
12484. 
[19] Gonias, S.L. and Pizzo, S.V. (1984) Ann. NY Acad. Sci. 421, 
457^171. 
[20] Ruff, E. and Rizzino, A. (1986) Biochem. Biophys. Res. Com-
mun. 138, 714-719. 
[21] Imber, M J . and Pizzo, S.V. (1981) J. Biol. Chem. 256, 8134-
8139. 
[22] Hall, P.K. and Roberts, R.C. (1978) Biochem. J. 173, 27-38. 
[23] Ganrot, P.O. (1967) Clin. Chim. Acta 16, 328-330. 
[24] Barrett, A.J., Brown, M.A. and Sayers, C.A. (1979) Biochem. J. 
181, 401^118. 
[25] Van Leuven, F., Cassiman, J.-J. and Van den Berghe, H. (1981) 
J. Biol. Chem. 256, 9016-9022. 
[26] Webb, D.J., Atkins, T.L., Crookston, K.P., Burmester, J.K., 
Qian, S.W. and Gonias, S.L. (1994) J. Biol. Chem. 269, 30402-
30406. 
[27] Burmester, J.K., Qian, S.W., Roberts, A.B., Huang, A., Ama-
tayakul-Chantler, S., Suardet, L., Odartchenko, N., Madri, J.A. 
and Sporn, M.B. (1993) Proc. Natl. Acad. Sci. USA 90, 8628-
8632. 
[28] Philip, A. and O'Connor-McCourt, M. (1991) J. Biol. Chem. 266, 
22290-22296. 
[29] Crookston, K.P., Webb, D.J., LaMarre, J. and Gonias, S.L. 
(1993) Biochem. J. 293, 443^150. 
[30] Lysiak, J.J., Hussaini, I.M., Webb, D.J., Glass II, W.J., Allietta, 
M. and Gonias, S.L. (1995) J. Biol. Chem. 270, 21919-21927. 
[31] Weaver, A.M., Owens, G.K. and Gonias, S.L. (1995) J. Biol. 
Chem. 270, 30741-30748. 
